AbbVie's Humira is a leading rheumatoid arthritis medication, but investors in this relatively new company are left wondering what the future holds once this drug loses patent protection. The Fool's brand-new premium report on the company answers the high-profile questions that AbbVie investors are asking. Simply click here now to claim your copy today.
Sanofi and Regeneron's Latest Partnership
May 15, 2013 | Comments (0)
DocumentId: 2434614, ~/Articles/ArticleHandler.aspx, 3/11/2014 5:07:46 PM